全文获取类型
收费全文 | 2379篇 |
免费 | 232篇 |
国内免费 | 19篇 |
专业分类
耳鼻咽喉 | 628篇 |
儿科学 | 11篇 |
妇产科学 | 8篇 |
基础医学 | 137篇 |
口腔科学 | 27篇 |
临床医学 | 75篇 |
内科学 | 84篇 |
皮肤病学 | 126篇 |
神经病学 | 54篇 |
特种医学 | 26篇 |
外科学 | 574篇 |
综合类 | 152篇 |
预防医学 | 61篇 |
眼科学 | 544篇 |
药学 | 60篇 |
1篇 | |
中国医学 | 29篇 |
肿瘤学 | 33篇 |
出版年
2024年 | 7篇 |
2023年 | 83篇 |
2022年 | 52篇 |
2021年 | 91篇 |
2020年 | 106篇 |
2019年 | 110篇 |
2018年 | 90篇 |
2017年 | 91篇 |
2016年 | 88篇 |
2015年 | 81篇 |
2014年 | 158篇 |
2013年 | 197篇 |
2012年 | 121篇 |
2011年 | 130篇 |
2010年 | 114篇 |
2009年 | 117篇 |
2008年 | 115篇 |
2007年 | 124篇 |
2006年 | 102篇 |
2005年 | 85篇 |
2004年 | 87篇 |
2003年 | 56篇 |
2002年 | 41篇 |
2001年 | 61篇 |
2000年 | 42篇 |
1999年 | 35篇 |
1998年 | 24篇 |
1997年 | 23篇 |
1996年 | 18篇 |
1995年 | 28篇 |
1994年 | 21篇 |
1993年 | 10篇 |
1992年 | 11篇 |
1991年 | 15篇 |
1990年 | 12篇 |
1989年 | 13篇 |
1988年 | 6篇 |
1987年 | 3篇 |
1986年 | 3篇 |
1985年 | 9篇 |
1984年 | 7篇 |
1983年 | 6篇 |
1982年 | 8篇 |
1981年 | 13篇 |
1980年 | 6篇 |
1979年 | 3篇 |
1978年 | 3篇 |
1975年 | 1篇 |
1973年 | 1篇 |
1968年 | 1篇 |
排序方式: 共有2630条查询结果,搜索用时 31 毫秒
1.
苏影 《中国继续医学教育》2021,(1)
目的探讨眼睑恶性肿瘤切除术中应用Z形皮瓣及推进皮瓣I期修复眼睑缺损的临床效果。方法将50例眼睑恶性肿瘤切除术患者按不同缝合方法分为两组,即对照组25例,术中直接缝合;观察组25例,术中行Z形皮瓣及推进皮瓣I期修复;比较两组眼睑修复效果。结果观察组术后皮瓣成活率96.0%、切口Ⅰ期愈合率100%、修复满意率92.0%,均高于对照组的72.0%、68.0%、56.0%,差异有统计学意义(P<0.05)。观察组术后并发症发生率低于对照组,但差异无统计学意义(P>0.05)。结论眼睑恶性肿瘤切除术中眼睑缺损修复时,采用Z形皮瓣及推进皮瓣,眼睑修复良好,患者修复满意率高,值得推广应用。 相似文献
2.
3.
目的 比较改良眶隔法和传统睑板法切开重睑术中的应用效果及对术后重睑形态、瘢痕发生率、角膜暴露率的影响。方法 选取2020年3月-2021年3月首都医疗爱育华医院收治的80例单睑患者,采用随机数字表法将其分对照组和观察组,各40例。对照组接受传统睑板法切开重睑术,观察组接受改良眶隔法切开重睑术,比较两组术后重睑形态、瘢痕发生率、角膜暴露率、并发症发生率。结果 观察组总有效率高于对照组,差异有统计学意义(P<0.05);观察组GAIS评分高于对照组,VAS评分低于对照组,差异有统计学意义(P<0.05);观察组右侧角膜暴露率增加值、左侧角膜暴露率增加值高于对照组,差异有统计学意义(P<0.05);观察组并发症发生率为5.00%,低于对照组的22.50%,差异有统计学意义(P<0.05)。结论 相比于传统睑板法切开重睑术,改良眶隔法切开重睑术不会过度增加术后角膜暴露率,术后瘢痕发生率更低,重睑形态更理想,患者接受度更高。 相似文献
4.
《Vaccine》2022,40(24):3380-3388
BackgroundWe evaluated the safety and immunogenicity of NVX-CoV2373, a recombinant SARS-CoV-2 nanoparticle vaccine, in healthy Japanese participants.MethodsThis phase 1/2, randomized, observer-blind, placebo-controlled trial conducted in Japan (two sites), enrolled healthy Japanese adults aged ≥ 20 years with no history/risk of SARS-CoV-2 infection and no prior exposure to other approved/investigational SARS-CoV-2 vaccines or treatments. Participants were stratified by age (< 65 or ≥ 65 years) and randomized to receive two doses of either NVX-CoV2373 (5 μg SARS-CoV-2 rS; 50 μg Matrix-M1) or placebo, 21 days apart. Primary outcomes were safety and immunogenicity assessed by serum IgG antibody levels against SARS-CoV-2 rS protein on day 36. Herein, we report the primary data analysis at 4 weeks after the second dose, ahead of 12-month follow-up completion (data cut-off: 8 May 2021).ResultsBetween 12 February 2021 and 17 March 2021, 326 subjects were screened, and 200 participants enrolled and randomized: NVX-CoV2373, n = 150; placebo, n = 50. Solicited adverse events (AEs) through 7 days after each injection occurred in 121/150 (80.7%) and 11/50 (22.0%) participants in the NVX-CoV2373 and placebo arms, respectively. In the NVX-CoV2373 arm, tenderness and injection site pain were the most frequently reported solicited AEs after each vaccination, irrespective of age. Robust immune responses occurred with NVX-CoV2373 (n = 150) by day 36: IgG geometric mean fold rise (95% confidence interval) 259 (219, 306); seroconversion rate 100% (97.6, 100). No such response occurred with placebo (n = 49).ConclusionTwo doses of NVX-CoV2373 given with a 21-day interval demonstrated acceptable safety and induced robust anti-SARS-CoV-2 immune responses in healthy Japanese adults. Funding: Takeda Pharmaceutical Company Limited and Japan Agency for Medical Research and Development (AMED). ClinicalTrials.gov identifier: NCT04712110. 相似文献
5.
6.
Christen L. Caloway MD Gillian R. Diercks MD MPH Gregory Randolph MD Christopher J. Hartnick MD MPH 《The Laryngoscope》2020,130(3):747-751
Ansa-to-recurrent laryngeal nerve (ANSA-RLN) reinnervation procedures are now often first-line treatments for some children with unilateral vocal fold immobility. Although many describe that children with prolonged denervation and true vocal fold atrophy should not undergo this procedure, there has been no gold-standard means of identifying true denervation. Here, we describe a novel technique using evoked vagal electromyography to predict degree of chronic nerve injury prior to recurrent laryngeal nerve reinnervation in children. This is a simple, readily available technique that may play an important role in predicting likelihood of success with pediatric ANSA-RLN reinnervation. Laryngoscope, 130:747–751, 2020 相似文献
7.
8.
Victoria A. Statler Frank R. Albano Jolanta Airey Daphne C. Sawlwin Alison Graves Jones Vince Matassa Esther Heijnen Jonathan Edelman Gary S. Marshall 《Vaccine》2019,37(2):343-351
Background
In the Southern Hemisphere 2010 influenza season, Seqirus’ split-virion, trivalent inactivated influenza vaccine was associated with increased reports of fevers and febrile reactions in young children. A staged clinical development program of a quadrivalent vaccine (Seqirus IIV4 [S-IIV4]; Afluria® Quadrivalent/Afluria Quad?/Afluria Tetra?), wherein each vaccine strain is split using a higher detergent concentration to reduce lipid content (considered the cause of the increased fevers and febrile reactions), is now complete.Methods
Children aged 6–59?months were randomized 3:1 and stratified by age (6–35?months/36–59?months) to receive S-IIV4 (n?=?1684) or a United States (US)-licensed comparator IIV4 (C-IIV4; Fluzone® Quadrivalent; n?=?563) during the Northern Hemisphere 2016–2017 influenza season. The primary objective was to demonstrate noninferior immunogenicity of S-IIV4 versus C-IIV4. Immunogenicity was assessed by hemagglutination inhibition (baseline, 28?days postvaccination). Solicited, unsolicited, and serious adverse events were assessed for 7, 28, and 180?days postvaccination, respectively.Results
S-IIV4 met the immunogenicity criteria for noninferiority. Adjusted geometric mean titer ratios (C-IIV4/S-IIV4) for the A/H1N1, A/H3N2, B/Yamagata, and B/Victoria strains were 0.79 (95% CI: 0.72, 0.88), 1.27 (1.15, 1.42), 1.12 (1.01, 1.24), and 0.97 (0.86, 1.09), respectively. Corresponding values for differences in seroconversion rates (C-IIV4 minus S-IIV4) were ?10.3 (?15.4, ?5.1), 2.6 (?2.5, 7.8), 3.1 (?2.1, 8.2), and 0.9 (?4.2, 6.1). Solicited, unsolicited, and serious adverse events were similar between vaccines in both age cohorts, apart from fever. Fever rates were lower with S-IIV4 (5.8%) than C-IIV4 (8.4%), with no febrile convulsions reported with either vaccine during the 7?days postvaccination.Conclusion
S-IIV4, manufactured with a higher detergent concentration, demonstrated noninferior immunogenicity to the US-licensed C-IIV4, with similar postvaccination safety and tolerability, in children aged 6–59?months. This completes the program demonstrating the immunogenicity and safety of S-IIV4 in participants aged 6?months and older.9.
《Journal of pharmaceutical sciences》2019,108(7):2500-2504
Accurately predicting the hepatic clearance of compounds using in vitro to in vivo extrapolation (IVIVE) is crucial within the pharmaceutical industry. However, several groups have recently highlighted the serious error in the process. Although empirical or regression-based scaling factors may be used to mitigate the common underprediction, they provide unsatisfying solutions because the reasoning behind the underlying error has yet to be determined. One previously noted trend was intrinsic clearance-dependent underprediction, highlighting the limitations of current in vitro systems. When applying these generated in vitro intrinsic clearance values during drug development and making first-in-human dose predictions for new chemical entities though, hepatic clearance is the parameter that must be estimated using a model of hepatic disposition, such as the well-stirred model. Here, we examine error across hepatic clearance ranges and find a similar hepatic clearance-dependent trend, with high clearance compounds not predicted to be so, demonstrating another gap in the field. 相似文献
10.
G. Desuter M. Dedry B. Schaar J.T. van Lith-Bijl P.P. van Benthem E.V. Sjögren 《European annals of otorhinolaryngology, head and neck diseases》2019,136(5):343-347
IntroductionStandardization of voice outcomes indicators (VOIs) is an important issue when it comes to evaluating and comparing surgical treatments for Unilateral Vocal Fold Paralysis (UVFP). In a recent review, 11 VOIs were found to represent 80% of the VOIs cited in the literature. A survey was launched among the European laryngologists to acquire surgeons’ opinions on the above mentioned preselected VOIs.Material and methodThe electronic survey took place between November and December 2016. Three general questions were asked about surgeon's practice setting(s) and experience. The eleven next questions concerned (a) surgeon's VOIs preference and (b) their estimates of post-operative target values, they would consider being satisfactory.ResultsThe response rate was 16% (50 surveys). The majority of responders worked in tertiary hospitals (50%), had 15 years of experience with UVFP and performed on average 20 UVFP related procedures a year. The VOIs that were favored by the responding surgeons were, in decreasing order of importance, Voice handicap Index (VHI-30), Maximum Phonation Time (MPT), GRBAS-I, Mean Airflow Rate (MeAF), Jitter and Shimmer. There was an excellent consensus on post-operative VOI target values between survey's results and the literature data, except for three VOIs that showed somewhat divergent tendencies (absolute VHI-30, Jitter and Shimmer).ConclusionsThree VOIs are favored by surgeons: VHI-30, MPT and GRBAS-I. Jitter and Shimmer, although very frequently reported and statistically valid in the literature, come last concerning surgeon's choice as VOI for UVFP treatment assessment. 相似文献